00:03 , Jul 18, 2019 |  BC Extra  |  Financial News

July 17 Financial Quick Takes: Chipscreen's Shanghai listing advances; plus Avrobio, Repligen and Seer

Chipscreen clears hurdle for Shanghai IPO With registration of its application by China Securities Regulatory Commission, Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, China) overcame the final hurdle for its proposed listing on Shanghai’s science and technology...
00:12 , Jun 7, 2019 |  BC Extra  |  Company News

June 6 Company Quick Takes: Take two for Celgene's ozanimod; plus Protalix, ABPI, Axovant and Mylan

Celgene resubmits NDA for ozanimod   FDA and EMA accepted submissions from Celgene Corp. (NASDAQ:CELG) for ozanimod to treat multiple sclerosis. The PDUFA date for the selective S1PR1 and S1PR5 modulator is March 25, 2020,...
19:42 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Vector copy number declines over time in four Fabry disease patients who received Avrobio gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase...
22:07 , Oct 1, 2018 |  BC Extra  |  Clinical News

Avrobio falls on data for Fabry gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase...
19:53 , Aug 13, 2018 |  BC Extra  |  Company News

Amicus prices Galafold at $315k per year

Amicus Therapeutics Inc. (NASDAQ:FOLD) said Monday that it will price Galafold migalastat at $315,000 per year and vowed to limit annual price increases of the Fabry disease drug to the rate of inflation. On Friday,...
20:35 , Aug 10, 2018 |  BC Extra  |  Company News

Amicus' Galafold wins accelerated approval from FDA

FDA granted accelerated approval to Galafold migalastat from Amicus Therapeutics Inc. (NASDAQ:FOLD) to treat Fabry disease in adults who have amenable mutations. Amicus said the U.S. approval is the first for a new Fabry disease...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
04:46 , Jun 21, 2018 |  BC Extra  |  Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
19:14 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Avrobio proposes $86.3M NASDAQ IPO

Avrobio Inc. (Cambridge, Mass.) proposed on May 25 to raise $86.3 million in an IPO underwritten by Morgan Stanley, Cowen, Wells Fargo and Wedbush PacGrow. In February, the cell therapy company raised $60 million in...
22:08 , May 25, 2018 |  BC Extra  |  Financial News

Eidos, Avrobio propose NASDAQ IPOs

Eidos Therapeutics Inc. (Palo Alto, Calif.) and Avrobio Inc. (Cambridge, Mass.) proposed NASDAQ IPOs on Friday. Eidos proposed to raise $115 million in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays. Last...